{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:12:47Z","timestamp":1771639967553,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.drudis.2015.10.015","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T20:36:20Z","timestamp":1446582980000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Emerging therapeutic targets for the treatment of hepatic fibrosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Paolo","family":"Fagone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa Rosanna","family":"Portale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Puleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2015.10.015_bib0305","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-10-40","article-title":"Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)","volume":"10","author":"Poynard","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0315","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2015.10.015_bib0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0325","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2015.10.015_bib0330","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.drudis.2013.01.006","article-title":"Targeting the epithelial cells in fibrosis: a new concept for an old disease","volume":"18","author":"Moll","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2015.10.015_bib0335","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/01.mcg.0000155516.02468.0f","article-title":"The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis","volume":"39","author":"Wells","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0340","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2015.10.015_bib0345","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.26053","article-title":"A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice","volume":"57","author":"Puche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0350","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1186\/1755-1536-5-S1-S27","article-title":"Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo","volume":"5","author":"Tacke","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.drudis.2015.10.015_bib0355","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2015.10.015_bib0360","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2015.10.015_bib0365","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0370","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0375","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1172\/JCI79327","article-title":"CCN1 induces hepatic ductular reaction through integrin \u03b1v\u03b25-mediated activation of NF-\u03baB","volume":"125","author":"Kim","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2015.10.015_bib0380","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/ijmm.2015.2264","article-title":"Identification of novel targets for the diagnosis and treatment of liver fibrosis","volume":"36","author":"Fagone","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.drudis.2015.10.015_bib0385","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hep.26429","article-title":"Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice","volume":"58","author":"Pradere","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0390","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0395","doi-asserted-by":"crossref","first-page":"G1248","DOI":"10.1152\/ajpgi.90223.2008","article-title":"Inflammasome-mediated regulation of hepatic stellate cells","volume":"296","author":"Watanabe","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0400","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2015.10.015_bib0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2007.08.008","article-title":"Liver X receptor and farnesoid X receptor as therapeutic targets","volume":"100","author":"Rader","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0410","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0415","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"Hern\u00e1ndez-Gea","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0420","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1038\/ncomms5451","article-title":"GIV\/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis","volume":"5","author":"Lopez-Sanchez","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2015.10.015_bib0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2015.01.036","article-title":"\u03b2-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis","volume":"63","author":"Kocabayoglu","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Wang","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0435","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0440","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.3748\/wjg.v20.i23.7452","article-title":"Inhibitory effects of rapamycin on the different stages of hepatic fibrosis","volume":"20","author":"Kim","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0445","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.transproceed.2013.04.011","article-title":"Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience","volume":"45","author":"Kelly","year":"2013","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.drudis.2015.10.015_bib0450","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2125.2010.03735.x","article-title":"Potential use of rapamycin in HIV infection","volume":"70","author":"Donia","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0455","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1248\/bpb.b14-00281","article-title":"Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway","volume":"37","author":"Jo","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.drudis.2015.10.015_bib0460","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of Galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2015.10.015_bib0465","first-page":"3331","article-title":"Hedgehog signaling regulates epithelial\u2013mesenchymal transition during biliary fibrosis in rodents and humans","volume":"118","author":"Omenetti","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2015.10.015_bib0470","doi-asserted-by":"crossref","first-page":"e23943","DOI":"10.1371\/journal.pone.0023943","article-title":"Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer","volume":"6","author":"Philips","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2015.10.015_bib0475","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1053\/j.gastro.2009.12.003","article-title":"Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection","volume":"138","author":"McHutchison","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0480","first-page":"1499","article-title":"Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis","volume":"49","author":"Ramalho","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0485","doi-asserted-by":"crossref","first-page":"G726","DOI":"10.1152\/ajpgi.00162.2009","article-title":"Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C","volume":"297","author":"Colmenero","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0490","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/gut.2006.107136","article-title":"A pilot study in patients with established advanced liver fibrosis using pirfenidone","volume":"55","author":"Armend\u00e1riz-Borunda","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2015.10.015_bib0495","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1542-3565(05)00404-0","article-title":"Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study","volume":"3","author":"Weng","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0500","first-page":"660","article-title":"Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis","volume":"42","author":"Rockey","year":"1994","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.drudis.2015.10.015_bib0505","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2015.10.015_bib0510","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease","volume":"81","author":"Kahal","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0515","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/gut.2007.120303","article-title":"Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo","volume":"57","author":"De Minicis","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2015.10.015_bib0520","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/gut.2005.076778","article-title":"Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats","volume":"55","author":"Ebrahimkhani","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2015.10.015_bib0525","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2015.10.015_bib0530","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0535","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1186\/1755-1536-5-S1-S24","article-title":"CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis","volume":"5","author":"Lipson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.drudis.2015.10.015_bib0540","first-page":"217","article-title":"Mesenchymal bone marrow-derived stem cells transplantation in patients with HCV related liver cirrhosis","volume":"2","author":"Lukashyk","year":"2014","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0545","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3275","article-title":"Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation","volume":"33","author":"Sampaziotis","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2015.10.015_bib0550","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2015.10.015_bib0555","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti\u2013transforming growth factor \u03b21 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.drudis.2015.10.015_bib0560","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/dtb.2015.7.0337","article-title":"Developments in the management of idiopathic pulmonary fibrosis","volume":"53","author":"DTB","year":"2015","journal-title":"Drug Ther. Bull."},{"key":"10.1016\/j.drudis.2015.10.015_bib0565","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2015.10.015_bib0570","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1172\/JCI7325","article-title":"An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response","volume":"104","author":"Chiaramonte","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2015.10.015_bib0575","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semarthrit.2012.06.001","article-title":"Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib","volume":"42","author":"Bournia","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.drudis.2015.10.015_bib0580","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-010-0142-x","article-title":"Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials","volume":"13","author":"Iwamoto","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.drudis.2015.10.015_bib0585","doi-asserted-by":"crossref","first-page":"23098","DOI":"10.1074\/jbc.M311430200","article-title":"Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK\/ERK","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2015.10.015_bib0590","first-page":"706","article-title":"Clarifying the use of ruxolitinib in patients with myelofibrosis","volume":"27","author":"Kremyanskaya","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.drudis.2015.10.015_bib0595","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.drudis.2015.01.001","article-title":"Pharmacological treatment of idiopathic pulmonary fibrosis: an update","volume":"20","author":"Spagnolo","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2015.10.015_bib0600","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1358\/dnp.2010.23.5.1444206","article-title":"PRM-151 (recombinant human serum amyloid P\/pentraxin 2) for the treatment of fibrosis","volume":"23","author":"Duffield","year":"2010","journal-title":"Drug News Perspect."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461500392X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461500392X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:23:59Z","timestamp":1761222239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964461500392X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S135964461500392X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2015.10.015","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic targets for the treatment of hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2015.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}